Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

GH - Guardant Health, Inc.

IEX Last Trade
30.24
-0.200   -0.661%

Share volume: 30,838
Last Updated: Fri 27 Dec 2024 08:30:25 PM CET

PREVIOUS CLOSE
CHG
CHG%
$30.44
-0.20
-0.66%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Historical prices Events Documents Notes Dividends
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
1.06%
1 Month
-10.63%
3 Months
37.11%
6 Months
7.99%
1 Year
11.96%
2 Year
22.40%
Key data
Stock price
$30.24
P/E Ratio 
-6.41
DAY RANGE
$30.14 - $31.38
EPS 
-$4.08
52 WEEK RANGE
$16.79 - $38.53
52 WEEK CHANGE
$15.97
MARKET CAP 
3.147 B
YIELD 
N/A
SHARES OUTSTANDING 
123.022 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,580,867
AVERAGE 30 VOLUME 
$1,431,647
Company detail
CEO: Helmy Eltoukhy
Region: US
Website: guardanthealth.com
Employees: 1,790
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry:
Sector:

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, LDT, CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible. Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients.

Recent news